読み込み中
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
前日終値
$2.54
+$0.01 · +0.40%
日中の時刻はETです。市場データは遅延する場合があります。
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
日中レンジ
現在 $2.54
52週レンジ
現在 $2.54
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
33
割高
センチメント
47
まちまち
リスク
46
やや高いリスク
モメンタム
44
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
日中レンジ
現在 $2.54
52週レンジ
現在 $2.54
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | 1600万 USD | — | — | — |
| 売上原価 | 2.48万 USD | — | — | — | — |
| 粗利益 | −2.48万 USD | 1600万 USD | — | — | — |
| 研究開発 | 1078.04万 USD | 489.69万 USD | 402.7万 USD | 344.89万 USD | 535.03万 USD |
| 販売・一般管理 | 574.51万 USD | 554.23万 USD | 466.31万 USD | 827.8万 USD | 532.36万 USD |
| 営業費用 | 943.44万 USD | 1148.97万 USD | 1258.69万 USD | 1230.95万 USD | 1423.58万 USD |
| 受取利息 | 89.4万 USD | 125.28万 USD | 17.4万 USD | 5.69万 USD | 1141 USD |
| 支払利息 | 2万 USD | 2.14万 USD | 1.11万 USD | 8599 USD | 6851 USD |
| 減価償却費と償却費 | 2.48万 USD | 1.92万 USD | 5.18万 USD | 4.16万 USD | 4.53万 USD |
| 営業利益 | −945.92万 USD | 451.03万 USD | −1258.69万 USD | −1230.95万 USD | −1423.58万 USD |
| 純利益 | −1083.52万 USD | 359.47万 USD | −1251.39万 USD | −1358.36万 USD | −1377.07万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
